AI Patient Education for Breast Cancer

This trial tests a new AI tool, the Generative AI Patient Education Module, designed to help breast cancer patients understand their condition and treatments. Researchers aim to determine if this tool is safe, accurate, and beneficial for patients. Participants will receive either immediate or delayed access to the tool and will provide feedback on its use over several months. The trial seeks individuals with Stage I-III breast cancer diagnosed in the last six months or those with Stage IV breast cancer undergoing a treatment change, who possess basic computer skills and internet access. As an unphased trial, this study offers patients the chance to contribute to innovative research that could enhance patient education and support.

The trial information does not specify whether you need to stop taking your current medications. It seems to focus on evaluating an AI tool for patient education, so it's unlikely that medication changes are required.

Research has shown that AI tools, such as the Generative AI Patient Education Module, are generally safe for teaching patients. One study examined AI's role in cancer care and found it did not cause harm when used to educate patients. The AI tool OpenEvidence uses guidelines from trusted cancer networks, ensuring the information it provides is safe and accurate. Previous research suggests that AI in patient education is well-received by users, with no reported negative effects. Thus, the AI tool is considered safe for educating patients about breast cancer.¹²³⁴⁵

Researchers are excited about the AI Patient Education Module for breast cancer because it uses a cutting-edge Generative AI tool, OpenEvidence CareConnect, to provide personalized health information. Unlike traditional educational resources, this tool employs a Retrieval-Augmented Generation (RAG) Large Language Model (LLM) to deliver tailored content that adapts to each patient's unique needs and questions. This approach could enhance patient understanding and engagement, empowering them to make more informed decisions about their care. Additionally, this real-time, dynamic educational support is a significant leap forward from static brochures or generic online resources.

This trial will evaluate the effectiveness of the Generative AI Patient Education Module, specifically the OpenEvidence CareConnect tool, in enhancing patient education for breast cancer. Participants will be divided into different arms: some will receive immediate access to the tool, while others will have delayed access. Studies have shown that generative AI tools can improve patient learning about cancer by providing accurate and helpful information. Specifically, AI models like ChatGPT have been tested for their ability to answer patient questions. These tools assist patients in understanding their diagnosis, treatment options, and self-care methods. AI in healthcare uses large amounts of data to predict outcomes and suggest treatments, enhancing patient education. While AI shows promise, evaluation methods still need standardization to ensure cultural appropriateness.¹²³⁶⁷